LABELS · b50198b2-d959-48cd-883d-3e1d30f9374b

Testosterone

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-09-30
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )]. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.2 )]. Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.2 ) and Patient Counseling Information ( 17 )]. WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning. Virilization has been reported in children who were secondarily exposed to testosterone gel ( 5.2 , 6.2 ). Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel ( 2.2 , 5.2 ). Healthcare providers should advise patients to strictly adhere to recommended instructions for use ( 2.2 , 5.2 , 17 ).

Indications and usage: exact source text

1 INDICATIONS AND USAGE Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )] . Testosterone gel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. ( 1 , 12.3 )

Full extracted label fields

application numbers

NDA022309

boxed warning exact

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )]. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.2 )]. Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.2 ) and Patient Counseling Information ( 17 )]. WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning. Virilization has been reported in children who were secondarily exposed to testosterone gel ( 5.2 , 6.2 ). Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel ( 2.2 , 5.2 ). Healthcare providers should advise patients to strictly adhere to recommended instructions for use ( 2.2 , 5.2 , 17 ).

brand names

Testosterone

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d84e5a6-11e9-4940-8991-21c611c4c32f

generic names

TESTOSTERONE

b50198b2-d959-48cd-883d-3e1d30f9374b

indications and usage exact

1 INDICATIONS AND USAGE Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )] . Testosterone gel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. ( 1 , 12.3 )

indications and usage tables exact

is original packager

true

manufacturer names

Prasco Laboratories

matched search terms

tumors

package ndcs

66993-951-88
66993-952-86
66993-952-30

product ndcs

66993-951
66993-952

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

TRANSDERMAL

rxcuis

1597076
1597126

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA022309

brand names

Testosterone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 642
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (co
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 0

current approval status

not_reconciled

duplicate text group

dup-57e5401ce05182e345b5

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-3222ccc08475ef97e38f

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

end: 59
end exclusive: true
exact text: is indicated
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 47

qualifier mentions

context exact
tosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absenc
kind
age
polarity
not_inferred
span
end
92
end exclusive
true
exact text
adult
label id
b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start
87
context exact
ndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
kind
biomarker
polarity
not_inferred
span
end
441
end exclusive
true
exact text
metals
label id
b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start
435

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 442
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA022309

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 808
end exclusive: true
exact text: lure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. The
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 243

current approval status

not_reconciled

duplicate text group

dup-69a344f25f79e478b08b

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-05617be68fadeca72814

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 608
end exclusive: true
exact text: These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 443

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA022309

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1004
end exclusive: true
exact text: age from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hyp
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 409

current approval status

not_reconciled

duplicate text group

dup-61c1ad7c96865863c13d

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-ca0c9a3d169075611628

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 804
end exclusive: true
exact text: Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 609

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA022309

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1109
end exclusive: true
exact text: ge. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 605

current approval status

not_reconciled

duplicate text group

dup-8a92de993372deee5e19

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-85b304fffc441158b5f5

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 909
end exclusive: true
exact text: These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 805

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · limitation of use

application numbers

NDA022309

brand names

Testosterone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1289
end exclusive: true
exact text: hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different do
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 710

current approval status

not_reconciled

duplicate text group

dup-1b70375a9453c3333351

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-d73c44a415e7d154697e

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1089
end exclusive: true
exact text: Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 910

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · limitation of use

application numbers

NDA022309

brand names

Testosterone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1437
end exclusive: true
exact text: ormal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacolo
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 890

current approval status

not_reconciled

duplicate text group

dup-bccb5996d8c216b72000

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-01ab825d1d0e56efc5d7

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

context exact
y and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populati
kind
age
polarity
not_inferred
span
end
1163
end exclusive
true
exact text
18 years
label id
b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start
1155

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1237
end exclusive: true
exact text: Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] .
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1090

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 7 · risk or warning

application numbers

NDA022309

brand names

Testosterone

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1651
end exclusive: true
exact text: ate-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )] . Testosterone gel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) (
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1038

current approval status

not_reconciled

duplicate text group

dup-147ee28fd1b3b8cd99fa

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-74abcae12c77ab92d10a

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1451
end exclusive: true
exact text: Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )] .
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1238

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · positive indication candidate

application numbers

NDA022309

brand names

Testosterone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2048
end exclusive: true
exact text: terone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )] . Testosterone gel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or applic
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1252

current approval status

not_reconciled

duplicate text group

dup-40e796ee1319d3a5e5af

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-7f243f8c2bd66a2e120f

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

end: 1487
end exclusive: true
exact text: is indicated
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1475

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1848
end exclusive: true
exact text: Testosterone gel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” have not been established.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1452

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · limitation of use

application numbers

NDA022309

brand names

Testosterone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2127
end exclusive: true
exact text: ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. ( 1 , 12.3 )
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1649

current approval status

not_reconciled

duplicate text group

dup-9dff07d9c1f3ec6c10e2

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-9d1ea8cd2dc655e468eb

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

context exact
y and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established.
kind
age
polarity
not_inferred
span
end
1928
end exclusive
true
exact text
18 years
label id
b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start
1920

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1959
end exclusive: true
exact text: ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1849

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 10 · risk or warning

application numbers

NDA022309

brand names

Testosterone

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2127
end exclusive: true
exact text: testosterone gel 1.62% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. ( 1 , 12.3 )
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1760

current approval status

not_reconciled

duplicate text group

dup-24763904616305803cb4

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-b96cc1d8fd0f7d5069c2

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2114
end exclusive: true
exact text: ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure.
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1960

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · unclassified context

application numbers

NDA022309

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2127
end exclusive: true
exact text: than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. ( 1 , 12.3 )
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 1915

current approval status

not_reconciled

duplicate text group

dup-eaeed92d46205bdcc91e

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-53a1ddaef94bceda43a5

label id

b50198b2-d959-48cd-883d-3e1d30f9374b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2127
end exclusive: true
exact text: ( 1 , 12.3 )
label id: b50198b2-d959-48cd-883d-3e1d30f9374b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 660bcdb4ae36805eabb086144d1e075893129f57d481e80186a6674d884c7bfb
start: 2115

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b50198b2-d959-48cd-883d-3e1d30f9374b%22

spl effective date

2024-09-30

spl set id

0d84e5a6-11e9-4940-8991-21c611c4c32f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice